Device Trial Radar · NCT05343065
A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B
Last checked: Nov 19, 2026Latest source record: Mar 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Jul 5, 2022
Primary completion
Dec 20, 2022
Study completion Dec 20, 2022
Sponsor
- Lead sponsor
- WelldocNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 25, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor.
Conditions
- Diabetes Mellitus
Interventions
BlueStar 10Device
An app that coaches individuals with diabetes and supports insulin-dosing based on continuous glucose monitor data
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of time a participant's glucose value is between 70 and 180 mg/dL will not be inferior to baseline.Time frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MedStar Health Research Institute
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.